Cabaletta Bio

Cabaletta Bio company information, Employees & Contact Information

Explore related pages

Related company profiles:

Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform encompasses two strategies: the CARTA (chimeric antigen receptor T cells for autoimmunity) strategy, with CABA-201, a 4-1BB-containing fully human CD19-CAR T, as the lead product candidate being evaluated in systemic lupus erythematosus and myositis, and the CAART (chimeric autoantibody receptor T cells) strategy, with multiple clinical-stage candidates, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK myasthenia gravis. The expanding CABA™ platform is designed to develop potentially curative therapies that offer deep and durable responses for patients with a broad range of autoimmune diseases. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA.

Company Details

Employees
176
Founded
-
Address
2929 Arch St,
Phone
​ +1 610 977 2422
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Philadelphia, Pennsylvania
Looking for a particular Cabaletta Bio employee's phone or email?

Cabaletta Bio Questions

News

Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant - Yahoo Finance

Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant Yahoo Finance

Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025 - The Globe and Mail

Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025 The Globe and Mail

Cabaletta Bio Reports Promising Initial Data from RESET-PV Trial of Rese-cel in Pemphigus Vulgaris Without Preconditioning - Quiver Quantitative

Cabaletta Bio Reports Promising Initial Data from RESET-PV Trial of Rese-cel in Pemphigus Vulgaris Without Preconditioning Quiver Quantitative

Complete B‑cell depletion in 2 of 3 PV patients — Cabaletta rese‑cel 1x10^6 cells/kg without preconditioning - Stock Titan

Complete B‑cell depletion in 2 of 3 PV patients — Cabaletta rese‑cel 1x10^6 cells/kg without preconditioning Stock Titan

Autoimmune Cell Therapy Pioneer Cabaletta Bio Featured at Morgan Stanley, Wells Fargo Healthcare Events - Stock Titan

Autoimmune Cell Therapy Pioneer Cabaletta Bio Featured at Morgan Stanley, Wells Fargo Healthcare Events Stock Titan

Cabaletta Bio to Present at Jefferies Global Healthcare Conference on June 4, 2025 - Quiver Quantitative

Cabaletta Bio to Present at Jefferies Global Healthcare Conference on June 4, 2025 Quiver Quantitative

Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance

Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update Yahoo Finance

Cabaletta Bio Raises $100M: New Funding Accelerates Revolutionary Autoimmune Disease Cell Therapies - Stock Titan

Cabaletta Bio Raises $100M: New Funding Accelerates Revolutionary Autoimmune Disease Cell Therapies Stock Titan

Cabaletta Bio Reports Positive Clinical Data from RESET™ Trials of Rese-cel in Autoimmune Diseases - Quiver Quantitative

Cabaletta Bio Reports Positive Clinical Data from RESET™ Trials of Rese-cel in Autoimmune Diseases Quiver Quantitative

Cabaletta Bio Announces Proposed Public Offering of Securities - Yahoo Finance

Cabaletta Bio Announces Proposed Public Offering of Securities Yahoo Finance

Autoimmune Disease Pioneer Cabaletta Bio Announces Major Public Offering With Jefferies Leading - Stock Titan

Autoimmune Disease Pioneer Cabaletta Bio Announces Major Public Offering With Jefferies Leading Stock Titan

Cabaletta Bio to Present Updated Clinical Data on Rese-cel at 2025 Scientific Conferences - Quiver Quantitative

Cabaletta Bio to Present Updated Clinical Data on Rese-cel at 2025 Scientific Conferences Quiver Quantitative

Cabaletta Bio Announces Pricing of Public Offering of Securities - Yahoo Finance

Cabaletta Bio Announces Pricing of Public Offering of Securities Yahoo Finance

Breakthrough: FDA Grants RMAT Status to Cabaletta's Myositis Therapy, Accelerating Path to 2027 BLA - Stock Titan

Breakthrough: FDA Grants RMAT Status to Cabaletta's Myositis Therapy, Accelerating Path to 2027 BLA Stock Titan

Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress - Yahoo Finance

Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress Yahoo Finance

Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts - Yahoo Finance

Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts Yahoo Finance

Cabaletta Bio’s CAR-T CABA-201 Effects Clinical Responses in Autoimmune Diseases - CGTLive®

Cabaletta Bio’s CAR-T CABA-201 Effects Clinical Responses in Autoimmune Diseases CGTLive®

A breakthrough for lupus treatment? Study explores CAR T-cell therapy for autoimmune disease - University of California - Davis Health

A breakthrough for lupus treatment? Study explores CAR T-cell therapy for autoimmune disease University of California - Davis Health

Cabaletta Bio: Still Optimistic, With News Being Guided To Share Soon (CABA) - Seeking Alpha

Cabaletta Bio: Still Optimistic, With News Being Guided To Share Soon (CABA) Seeking Alpha

Cabaletta Bio (CABA) Upgraded to Buy: Here's Why - Yahoo Finance

Cabaletta Bio (CABA) Upgraded to Buy: Here's Why Yahoo Finance

Cabaletta Bio’s CAR-T CABA-201 Shows Initial Signs of Efficacy in Myositis and Lupus Trials - CGTLive®

Cabaletta Bio’s CAR-T CABA-201 Shows Initial Signs of Efficacy in Myositis and Lupus Trials CGTLive®

Cabaletta Bio’s CAR-T CABA-201 Shows Safety for First Patients Dosed in Myositis and Lupus Trials - CGTLive®

Cabaletta Bio’s CAR-T CABA-201 Shows Safety for First Patients Dosed in Myositis and Lupus Trials CGTLive®

Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform - Business Wire

Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform Business Wire

The Lupus Approach: CAR-T Begins the Jump from Blood Cancers to Autoimmune Disease - HCPLive

The Lupus Approach: CAR-T Begins the Jump from Blood Cancers to Autoimmune Disease HCPLive

IASO Biotherapeutics and Cabaletta Bio Announce Exclusive Worldwide License Agreement for Clinically Validated CD19 Binder - PR Newswire

IASO Biotherapeutics and Cabaletta Bio Announce Exclusive Worldwide License Agreement for Clinically Validated CD19 Binder PR Newswire

Cabaletta Bio: Finding Optimism In Dire Straits (NASDAQ:CABA) - Seeking Alpha

Cabaletta Bio: Finding Optimism In Dire Straits (NASDAQ:CABA) Seeking Alpha

Cellares and Cabaletta Bio Complete Manufacturing Technology Adoption Program - Genetic Engineering and Biotechnology News

Cellares and Cabaletta Bio Complete Manufacturing Technology Adoption Program Genetic Engineering and Biotechnology News

Cabaletta Bio Launches Public Offering Of Stock And Warrants - Nasdaq

Cabaletta Bio Launches Public Offering Of Stock And Warrants Nasdaq

Cabaletta Bio: Sector Headwinds And Funding Issues, But Also Some Clear Clinical Direction - Seeking Alpha

Cabaletta Bio: Sector Headwinds And Funding Issues, But Also Some Clear Clinical Direction Seeking Alpha

Cabaletta Bio, Inc.'s (NASDAQ:CABA) latest 25% decline adds to one-year losses, institutional investors may consider drastic measures - Yahoo Finance

Cabaletta Bio, Inc.'s (NASDAQ:CABA) latest 25% decline adds to one-year losses, institutional investors may consider drastic measures Yahoo Finance

Cabaletta Bio stock tumbles after pricing $100 million public offering - Investing.com

Cabaletta Bio stock tumbles after pricing $100 million public offering Investing.com

Is Cabaletta Bio (NASDAQ:CABA) In A Good Position To Invest In Growth? - simplywall.st

Is Cabaletta Bio (NASDAQ:CABA) In A Good Position To Invest In Growth? simplywall.st

Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment (NASDAQ:CABA) - Seeking Alpha

Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment (NASDAQ:CABA) Seeking Alpha

Cabaletta Bio Stock Surges To 2-Month High On Autoimmune Therapy Progress; Retail’s Pleased - Stocktwits

Cabaletta Bio Stock Surges To 2-Month High On Autoimmune Therapy Progress; Retail’s Pleased Stocktwits

Myasthenia Gravis mRNA CAR-T Demonstrates Clinically Meaningful Improvements in Phase 2a Trial - CGTLive®

Myasthenia Gravis mRNA CAR-T Demonstrates Clinically Meaningful Improvements in Phase 2a Trial CGTLive®

Cabaletta Bio and Artisan Bio Announce Gene Editing - GlobeNewswire

Cabaletta Bio and Artisan Bio Announce Gene Editing GlobeNewswire

Cabaletta Bio's and Gracell's stock plunges as FDA probes risks of CAR-T therapy - MarketWatch

Cabaletta Bio's and Gracell's stock plunges as FDA probes risks of CAR-T therapy MarketWatch

CABA Stock Price and Chart — NASDAQ:CABA - TradingView

CABA Stock Price and Chart — NASDAQ:CABA TradingView

Top Cabaletta Bio Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant